{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T07:51:08Z","timestamp":1792569068659,"version":"4.5.0"},"reference-count":20,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T00:00:00Z","timestamp":1638489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R44CA162744"],"award-info":[{"award-number":["1R44CA162744"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Prediction of radiotherapy (RT) benefit after breast-conserving surgery (BCS) for DCIS is crucial. The aim was to validate a biosignature, DCISionRT\u00ae, in the SweDCIS randomized trial. Women were randomly assigned to RT or not after BCS, between 1987 and 2000. Tumor blocks were collected, and slides were sent to PreludeDxTM for testing. In 504 women with complete data and negative margins, DCISionRT divided 52% women into Elevated (DS &gt; 3) and 48% in Low (DS \u2264 3) Risk groups. In the Elevated Risk group, RT significantly decreased relative 10-year ipsilateral total recurrence (TotBE) and 10-year ipsilateral invasive recurrence (InvBE) rates, HR 0.32 and HR 0.24, with absolute decreases of 15.5% and 9.3%. In the Low Risk group, there were no significant risk differences observed with radiotherapy. Using a cutoff of DS &gt; 3.0, the test was not predictive for RT benefit (p = 0.093); however, above DS &gt; 2.8 RT benefit was greater for InvBE (interaction p = 0.038). Recurrences at 10 years without radiotherapy increased significantly per 5 DS units (TotBE HR:1.5 and InvBE HR:1.5). Continuous DS was prognostic for TotBE risk although categorical DS did not reach significance. Absolute 10-year TotBE and InvBE risks appear sufficiently different to indicate that DCISionRT can aid physicians in selecting individualized adjuvant DCIS treatment strategies. Further analyses are planned in combined cohorts to increase statistical power.<\/jats:p>","DOI":"10.3390\/cancers13236103","type":"journal-article","created":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T20:59:33Z","timestamp":1638737973000},"page":"6103","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Prognostic Risk Assessment and Prediction of Radiotherapy Benefit for Women with Ductal Carcinoma In Situ (DCIS) of the Breast, in a Randomized Clinical Trial (SweDCIS)"],"prefix":"10.3390","volume":"13","author":[{"given":"Fredrik","family":"W\u00e4rnberg","sequence":"first","affiliation":[{"name":"Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 405-30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4841-2672","authenticated-orcid":false,"given":"Per","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 405-30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Holmberg","sequence":"additional","affiliation":[{"name":"Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, 405-30 Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Sandelin","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 77 Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat W.","family":"Whitworth","sequence":"additional","affiliation":[{"name":"Nashville Breast Center, Nashville, TN 37203, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jess","family":"Savala","sequence":"additional","affiliation":[{"name":"PreludeDx, Laguna Hills, CA 92653, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Barry","sequence":"additional","affiliation":[{"name":"Todd S. Barry Dx, Mission Viejo, CA 92691, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Leesman","sequence":"additional","affiliation":[{"name":"PreludeDx, Laguna Hills, CA 92653, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8584-4947","authenticated-orcid":false,"given":"Steven P.","family":"Linke","sequence":"additional","affiliation":[{"name":"Steven P. Linke Consulting, Carlsbad, CA 92009, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9538-4016","authenticated-orcid":false,"given":"Steven C.","family":"Shivers","sequence":"additional","affiliation":[{"name":"PreludeDx, Laguna Hills, CA 92653, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Vicini","sequence":"additional","affiliation":[{"name":"Genesis Care, Farmington Hills, MI 48334, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Weinmann","sequence":"additional","affiliation":[{"name":"Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Bruce","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of Melbourne, Melbourne VIC 3010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy","family":"Bremer","sequence":"additional","affiliation":[{"name":"PreludeDx, Laguna Hills, CA 92653, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/jncimonographs\/lgq039","article-title":"Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast","volume":"2010","author":"Collaborative","year":"2010","journal-title":"J. Natl. Cancer Institute. Monogr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7150\/jca.2.232","article-title":"Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review","volume":"2","author":"Lari","year":"2011","journal-title":"J. Cancer"},{"key":"ref_3","first-page":"303","article-title":"Management of ductal carcinoma in situ in the modern era","volume":"73","author":"Khan","year":"2018","journal-title":"Minerva Chir."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rakovitch, E., Nofech-Mozes, S., Hanna, W., Sutradhar, R., Baehner, F.L., Miller, D.P., Fong, C., Gu, S., Tuck, A., and Sengupta, S. (2017). Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ. J. Natl. Cancer Inst., 109.","DOI":"10.1093\/jnci\/djw256"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.surg.2019.04.044","article-title":"Evaluating patterns of utilization of gene signature panels and impact on treatment patterns in patients with ductal carcinoma in situ of the breast","volume":"166","author":"Bhutiani","year":"2019","journal-title":"Surgery"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-050715-104920","article-title":"Controversies in the Treatment of Ductal Carcinoma in situ","volume":"68","author":"Barrio","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1158\/1078-0432.CCR-19-1152","article-title":"Validation of a Ductal Carcinoma In Situ Biomarker Profile for Risk of Recurrence after Breast-Conserving Surgery with and without Radiotherapy","volume":"26","author":"Weinmann","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5895","DOI":"10.1158\/1078-0432.CCR-18-0842","article-title":"A Biological Signature for Breast Ductal Carcinoma In Situ to Predict Radiotherapy Benefit and Assess Recurrence Risk","volume":"24","author":"Bremer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_9","unstructured":"Warnberg, F., Garmo, H., Folkvaljon, Y., Holmberg, L., Karlsson, P., Sandelin, K., Linke, S., Simin, K., Leesman, G., and Barry, T. (2021, October 01). A Validation of DCIS Biological Risk Profile in a Randomised Study for Radiation Therapy with 20 Year Follow-Up (SweDCIS). Available online: https:\/\/www.sabcs.org\/Portals\/SABCS2016\/Documents\/SABCS-2017-Abstracts.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3613","DOI":"10.1200\/JCO.2014.56.2595","article-title":"Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial","volume":"32","author":"Warnberg","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1080\/02841860600681569","article-title":"SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening","volume":"45","author":"Emdin","year":"2006","journal-title":"Acta Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2014.57.9029","article-title":"RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation","volume":"33","author":"McCormick","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejca.2006.09.018","article-title":"Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial","volume":"43","author":"Ringberg","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1200\/JCO.2015.60.8588","article-title":"Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study","volume":"33","author":"Solin","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.21.01083","article-title":"Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology\/RTOG 9804","volume":"39","author":"McCormick","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1245\/s10434-021-09903-1","article-title":"Correction to: The Clinical Utility of DCISionRT((R)) on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery","volume":"28","author":"Shah","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1080\/0284186X.2016.1211317","article-title":"A validation of DCIS registration in a population-based breast cancer quality register and a study of treatment and prognosis for DCIS during 20 years","volume":"55","author":"Wadsten","year":"2016","journal-title":"Acta Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vicini, F., Shah, C., Shivers, S., He, W., Karlsson, P., Holmberg, E., Leo, M.C., Huang, Y., Weinmann, S., and Warnberg, F. (2020, January 8\u201311). Abstract PD5-04: DCIS biosignature reclassified patients who met RTOG 9804 or ECOG-ACRIN E5194 \u2018low-risk\u2019 clinico-pathologic criteria into an elevated invasive risk group who benefited significantly from radiation therapy. Proceedings of the San Antonio Breast Cancer Virtual Symposium, San Antonio, TX, USA.","DOI":"10.1158\/1538-7445.SABCS20-PD5-04"},{"key":"ref_19","unstructured":"Royston, P., and Lambert, P.C. (2011). Flexible Parametric Survival Analysis in Stata: Beyond the Cox Model, Stata Press."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1002\/sim.7448","article-title":"Parametric multi-state survival models: Flexible modelling allowing transition-specific distributions with application to es-timating clinically useful measures of effect differences","volume":"36","author":"Crowther","year":"2017","journal-title":"Stat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6103\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:39:26Z","timestamp":1760168366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":20,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13236103"],"URL":"https:\/\/doi.org\/10.3390\/cancers13236103","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]}}}